CAL-101 – HEMATOLOGIC MALIGNANCIES

CAL-101 is an oral, small molecule PI3K Delta selective inhibitor, a first in class compound, in clinical development for the treatment of patients with hematologic malignancies.

Oncology

CAL-101 Hematologic Malignancies

Ongoing Trials Please visit the Clinical Trials page for additional information.

  • Clinical Proof of Concept Study in Patients with Hematologic Malignancies
  • Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
  • Combination trial evaluating CAL-101 in combination with rituximab, bendamustine, and the combination of rituxamub and bendamstine in patients with indolent NHL and CLL

Completed Trials

  • Phase 1 evaluation in normal human volunteers demonstrated tolerability with twice daily dosing

Upcoming Trials

  • Calistoga Pharmaceuticals Plans to Advance CAL-101 into Registration Trials in the second half of 2010

CAL-101 is currently being investigated in clinical trials and has not received U.S. F.D.A. approval. Calistoga Pharmaceuticals does not claim that this technology or any of its product candidates are safe or will be effective in preventing, treating or curing any disease or condition.

Recommended Websites